Submucosal Digestive Lesions — Endoscopic Ultrasound Diagnosis

What Are Submucosal Lesions?

Submucosal lesions (SMLs), also known as subepithelial lesions, are abnormal growths that originate from the deeper layers of the digestive tract wall — beneath the surface mucosal lining. Unlike polyps, which grow from the surface layer, submucosal lesions push the overlying mucosa upward, creating a characteristic smooth, round elevation visible during endoscopy. The mucosa covering the lesion typically appears normal.

Submucosal lesions are often discovered incidentally during endoscopy performed for other reasons. They are found in approximately 1 in 300 upper endoscopies. While many are benign and require no treatment, some carry malignant potential and require careful evaluation to determine the appropriate management.

Types of Submucosal Lesions

• Gastrointestinal Stromal Tumors (GISTs) — the most clinically significant type. GISTs arise from the interstitial cells of Cajal and can range from benign to highly malignant. Size, mitotic rate, and location determine the risk of malignancy. Most commonly found in the stomach.
• Leiomyomas — benign smooth muscle tumors, most common in the esophagus. They have essentially no malignant potential and often require no treatment.
• Lipomas — benign fatty tumors that appear as soft, yellowish submucosal elevations. The classic "pillow sign" (indentation with forceps pressure) is characteristic. No malignant potential.
• Neuroendocrine Tumors (NETs) — tumors arising from neuroendocrine cells. Behavior varies from indolent to aggressive depending on the type, grade, and location (gastric, rectal, small bowel).
• Schwannomas — benign nerve sheath tumors that can mimic GISTs in appearance. Almost exclusively benign in the GI tract.
• Granular cell tumors — uncommon tumors most often found in the esophagus, usually benign
• Ectopic pancreas — islands of pancreatic tissue in the stomach wall, a developmental variant with no clinical significance
• Duplication cysts — congenital cystic structures within the GI wall

Symptoms

The majority of submucosal lesions are asymptomatic and discovered incidentally during endoscopy. When symptoms do occur, they may include:

• Vague abdominal discomfort — rarely directly attributable to the lesion
• GI bleeding — larger lesions, especially GISTs, can ulcerate through the overlying mucosa and bleed
• Obstruction — very large lesions may cause symptoms of blockage
• Dysphagia — esophageal lesions may cause difficulty swallowing if sufficiently large

The Role of EUS in Diagnosis

Endoscopic Ultrasound (EUS) is the most important diagnostic tool for evaluating submucosal lesions. EUS allows precise characterization by determining:

• Layer of origin — the GI wall has five distinct layers visible on EUS. Identifying which layer the lesion arises from significantly narrows the differential diagnosis. For example, GISTs typically arise from the fourth layer (muscularis propria), while lipomas arise from the third layer (submucosa).
• Size measurement — accurate size determination is essential for risk assessment and management planning
• Echogenicity and internal features — hypoechoic, hyperechoic, or mixed patterns; presence of cystic spaces, calcifications, or irregular borders
• Margins and surrounding structures — sharp versus irregular borders, involvement of adjacent organs or vessels

EUS-Guided Biopsy (FNA/FNB)

When tissue diagnosis is needed, EUS-guided tissue sampling provides material for pathological analysis:

• Fine-Needle Aspiration (FNA) — uses a thin needle to aspirate cells for cytological examination
• Fine-Needle Biopsy (FNB) — newer core-biopsy needles obtain tissue fragments that preserve architecture, improving diagnostic accuracy and allowing immunohistochemical staining (essential for distinguishing GISTs from other mesenchymal tumors)
• Key immunohistochemical markers: CD117 (c-KIT) and DOG1 for GISTs; S-100 for schwannomas; desmin and SMA for leiomyomas
• Tissue sampling is particularly important for lesions larger than 20 mm or those with suspicious EUS features

When Surgery Is Needed

Surgical resection is recommended for:

• Confirmed GISTs larger than 20 mm (some guidelines suggest resection for all GISTs regardless of size)
• Lesions with high-risk EUS features: irregular borders, heterogeneous echotexture, cystic spaces, rapid growth on surveillance
• Symptomatic lesions causing bleeding or obstruction
• NETs with features suggesting aggressive behavior (size over 10-20 mm, invasion of muscularis propria)
• Lesions where tissue diagnosis cannot be obtained and malignancy cannot be excluded

Surgical approaches include laparoscopic wedge resection (for gastric lesions) and segmental resection. Endoscopic resection techniques (submucosal tunneling endoscopic resection — STER) are emerging alternatives for selected cases.

Surveillance Approach

Small, asymptomatic submucosal lesions with benign EUS features can be safely monitored with periodic EUS:

• Lesions under 20 mm with benign features — EUS follow-up in 6-12 months, then annually for 2-3 years if stable
• Confirmed lipomas and leiomyomas — no further follow-up required in most cases
• Small rectal NETs (under 10 mm, low-grade) — may be removed endoscopically and followed
• Any change in size, echogenicity, or symptom development should prompt reassessment and consideration of tissue sampling or resection

Prognosis

The prognosis of submucosal lesions varies greatly by type:

• Lipomas, leiomyomas, schwannomas — excellent prognosis, benign behavior
• GISTs — prognosis depends on size, mitotic rate, and location. Small, low-risk GISTs have an excellent prognosis. Larger, high-risk GISTs may recur even after complete resection but respond well to targeted therapy (imatinib).
• NETs — highly variable, from indolent type 1 gastric NETs (excellent prognosis) to aggressive high-grade neuroendocrine carcinomas
• Accurate diagnosis through EUS with tissue sampling is the key to determining prognosis and guiding management.